<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-159964" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Fingolimod</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lobaina</surname>
            <given-names>Milena</given-names>
          </name>
          <aff>University Of Texas Medical Branch</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shanina</surname>
            <given-names>Elena</given-names>
          </name>
          <aff>University of Texas Medical Branch</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Milena Lobaina declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Elena Shanina declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>30</day>
          <month>5</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-159964.s1" sec-type="Indications">
        <title>Indications</title>
        <p content-type="pubmed-excerpt">Fingolimod is the first oral disease-modifying&#x000a0;agent&#x000a0;approved by the US Food and Drug Administration (FDA) for treating relapsing-remitting multiple sclerosis (RRMS).<xref ref-type="bibr" rid="article-159964.r1">[1]</xref>&#x000a0;This drug is also indicated for&#x000a0;active secondary progressive disease with superimposed relapse and for treating clinically isolated syndromes.<xref ref-type="bibr" rid="article-159964.r2">[2]</xref><xref ref-type="bibr" rid="article-159964.r3">[3]</xref>&#x000a0;</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>The efficacy of fingolimod in treating RRMS has been&#x000a0;demonstrated&#x000a0;in 3 separate double-blind, randomized, phase III clinical trials. In the placebo-controlled FREEDOMS trial (FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis), fingolimod&#x000a0;demonstrated improved relapse rate, decreased disease disability progression, reduced number of active or enlarging magnetic resonance imaging (MRI) lesions, and brain atrophy over 2 years. The FREEDOMS II trial evaluated fingolimod's safety profile and found that daily administration of 0.5 mg had a favorable benefit-risk ratio when treating RRMS.</p>
        <p>The TRANSFORMS trial&#x000a0;(Trial Assessing Injectable Interferon versus FTY720 Oral in Relapsing-Remitting Multiple Sclerosis)&#x000a0;demonstrated&#x000a0;the superiority of fingolimod therapy in reducing disease activity and relapses in RRMS when compared to interferon &#x003b2;-1a.<xref ref-type="bibr" rid="article-159964.r2">[2]</xref><xref ref-type="bibr" rid="article-159964.r4">[4]</xref><xref ref-type="bibr" rid="article-159964.r5">[5]</xref>&#x000a0;Studies in specific patient populations, including the IRST LATAM study, analyzed fingolimod's effect on Latin American patients with diagnosed multiple sclerosis. The medication's pharmacodynamics and safety profile did not differ among these patients.<xref ref-type="bibr" rid="article-159964.r6">[6]</xref></p>
      </sec>
      <sec id="article-159964.s2" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Fingolimod is a nonselective functional antagonist of sphingosine-1-phosphate receptors (S1PRs).<xref ref-type="bibr" rid="article-159964.r1">[1]</xref>&#x000a0;Since the emergence of fingolimod in 2010 as the first medication of&#x000a0;this class,&#x000a0;similar medications with higher receptor specificity have been synthesized and FDA-approved, such as siponimod (2019), ozanimod (2020), and ponesimod (2021).<xref ref-type="bibr" rid="article-159964.r3">[3]</xref></p>
        <p>Fingolimod's molecular structure resembles a bioactive lipid called sphingosine,&#x000a0;which is produced&#x000a0;in the cell membrane and transported extracellularly to modulate a series of biological responses. Sphingosine receptors are a group of&#x000a0;5 G-protein&#x02013;coupled receptors expressed throughout the body and are associated with&#x000a0;various biological processes.<xref ref-type="bibr" rid="article-159964.r5">[5]</xref><xref ref-type="bibr" rid="article-159964.r7">[7]</xref></p>
        <p>S1PRs (S1PR1, S1PR2, and S1PR3) are highly expressed within the brain, heart, spleen, lung, thymus, and skeletal muscle cells.<xref ref-type="bibr" rid="article-159964.r5">[5]</xref>&#x000a0;The S1PR signaling pathway is an essential regulator of lymphocyte trafficking from lymph nodes to circulation.<xref ref-type="bibr" rid="article-159964.r8">[8]</xref>&#x000a0;Additionally, this pathway mediates several nonimmune essential functions, such as vascular and neurogenic angiogenesis, vessel permeability, basal vascular tone, dendritic cell migration, and bacteremia.<xref ref-type="bibr" rid="article-159964.r9">[9]</xref><xref ref-type="bibr" rid="article-159964.r8">[8]</xref><xref ref-type="bibr" rid="article-159964.r10">[10]</xref><xref ref-type="bibr" rid="article-159964.r11">[11]</xref><xref ref-type="bibr" rid="article-159964.r12">[12]</xref>&#x000a0;S1PR1 and S1PR3 are expressed in the membranes of the atrium myocytes and provide a chronotropic effect on the heart.<xref ref-type="bibr" rid="article-159964.r5">[5]</xref>&#x000a0;S1PR4 is involved in immunological aspects of carcinogenesis by regulating the proliferation and survival of natural killer cells, while both S1PR4 and S1PR5 modulate innate immune cell response.<xref ref-type="bibr" rid="article-159964.r13">[13]</xref><xref ref-type="bibr" rid="article-159964.r14">[14]</xref></p>
        <p>Fingolimod requires in vivo phosphorylation to activate S1PR.<xref ref-type="bibr" rid="article-159964.r15">[15]</xref><xref ref-type="bibr" rid="article-159964.r16">[16]</xref>&#x000a0;The drug binds nonselectively to S1PR, primarily receptors 1, 3, 4, and 5.<xref ref-type="bibr" rid="article-159964.r5">[5]</xref>&#x000a0;This binding leads to receptor internalization and recycling, except for S1PR1, which undergoes irreversible degradation within the formed endosomes.<xref ref-type="bibr" rid="article-159964.r1">[1]</xref>&#x000a0;Continued administration&#x000a0;causes a stepwise&#x000a0;reduction in available receptors and desensitization.<xref ref-type="bibr" rid="article-159964.r1">[1]</xref>&#x000a0;Fingolimod Fingolimod exhibits a high affinity for S1PR1, which is prominently expressed in lymphocytes.<xref ref-type="bibr" rid="article-159964.r17">[17]</xref><xref ref-type="bibr" rid="article-159964.r5">[5]</xref>&#x000a0;Activation of S1PR1 by sphingosine-1-phosphate stimulates lymphocyte migration, thereby promoting inflammation. Therefore, inhibiting S1PR1 with fingolimod reduces circulating lymphocytes and limits the inflammatory response. Fingolimod affects T- and B-cell trafficking, as well as oligodendrocytes, where S1PR5 receptors are expressed.<xref ref-type="bibr" rid="article-159964.r1">[1]</xref>&#x000a0;Moreover, fingolimod crosses the blood-brain barrier, helping to preserve its integrity and potentially reducing brain edema.<xref ref-type="bibr" rid="article-159964.r18">[18]</xref><xref ref-type="bibr" rid="article-159964.r19">[19]</xref></p>
        <p>The cardiovascular effect of fingolimod is directly related to S1PR1 activation. Fingolimod binding to S1PR1 on endothelial cells leads to enhanced endothelial cell junction and decreased vascular permeability. This function is dose-dependent, as prolonged fingolimod administration causes&#x000a0;vascular injury and increased permeability. Fingolimod causes bradycardia and hypotension by activating endothelial nitric oxide synthase&#x02014;a Gi-protein&#x02013;coupled process.<xref ref-type="bibr" rid="article-159964.r1">[1]</xref>&#x000a0;Additionally, the binding of fingolimod to S1PR3 leads to neuronal regeneration,&#x000a0;bradycardia,&#x000a0;arterial vasodilation,&#x000a0;and macrophage phagocytosis.<xref ref-type="bibr" rid="article-159964.r20">[20]</xref><xref ref-type="bibr" rid="article-159964.r21">[21]</xref><xref ref-type="bibr" rid="article-159964.r22">[22]</xref><xref ref-type="bibr" rid="article-159964.r23">[23]</xref>&#x000a0;Furthermore, the drug may suppress the immune response by downregulating Th17 proliferation and Th17-central memory cells in the peripheral circulation, thereby substantially decreasing the neuroinflammation seen in multiple sclerosis.<xref ref-type="bibr" rid="article-159964.r24">[24]</xref><xref ref-type="bibr" rid="article-159964.r25">[25]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:&#x000a0;</bold>Fingolimod has an oral bioavailability of 93%, unaffected by food intake. The drug achieves a steady state within 8 to 36 hours after administration, with a half-life ranging from 6 to 9 days.<xref ref-type="bibr" rid="article-159964.r4">[4]</xref></p>
        <p><bold>Distribution:&#x000a0;</bold>Approximately 86% of fingolimod is distributed via red blood cells, with a volume of distribution of approximately 1200 &#x000b1; 260 L.</p>
        <p><bold>Metabolism:&#x000a0;</bold>Fingolimod undergoes metabolism via 3 different pathways. The first pathway involves reversible phosphorylation, catalyzed by lipid phosphate phosphohydrolases and specific sphingosine 1-phosphate phosphatase.<xref ref-type="bibr" rid="article-159964.r4">[4]</xref>&#x000a0;The second pathway includes fingolimod hydroxylation and oxidation by enzymes such as CYP4F2 and other CYP4F enzymes aimed at neutralizing carboxylic acid metabolites excreted by the kidneys.<xref ref-type="bibr" rid="article-159964.r4">[4]</xref>&#x000a0;The third metabolic pathway leads&#x000a0;to the formation of nonpolar ceramides by dihydroceramide synthase, contributing to the least concentration in the blood.<xref ref-type="bibr" rid="article-159964.r1">[1]</xref>&#x000a0;</p>
        <p><bold>Elimination:&#x000a0;</bold>Fingolimod is primarily excreted in urine (81%), with the most common metabolic products in urine being the butanoic acid metabolites. Fingolimod and fingolimod-phosphate, comprising less than 2.5% of the dose, are detectable in both blood and feces.<xref ref-type="bibr" rid="article-159964.r4">[4]</xref></p>
        <p><bold>Protein binding:&#x000a0;</bold>Fingolimod and its active metabolite, fingolimod phosphate, exhibit high binding to plasma albumin (&#x0003e;99.7%) and lipoproteins. This protein affinity is independent of renal or hepatic dysfunction.<xref ref-type="bibr" rid="article-159964.r1">[1]</xref><xref ref-type="bibr" rid="article-159964.r4">[4]</xref>&#x000a0;However, even at a steady state, the medication's plasma concentration remains consistently low; thus, reducing fingolimod's affinity for plasma proteins does not increase&#x000a0;its toxicity.<xref ref-type="bibr" rid="article-159964.r4">[4]</xref></p>
      </sec>
      <sec id="article-159964.s3" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Fingolimod formulations are available as oral capsules in strengths of 0.25 mg and 0.5 mg. Food consumption does not affect drug administration. The recommended dosage for adults with a body weight of less than or equal to 40 kg (88 lb) is a 0.5 mg tablet once daily. For pediatric patients aged 10 or older with a body weight of less than 40 kg (88 lb), the recommended fingolimod&#x000a0;dosage is a 0.25 mg tablet once daily.</p>
        <p>
<bold>Various Therapeutic Approaches of&#x000a0;Fingolimod for Relapsing-Remitting Multiple Sclerosis</bold>
</p>
        <p><bold>Fingolimod as first-line therapy for RRMS: </bold>Fingolimod has been effective for various conditions, as mentioned below.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Fingolimod can be used as first-line therapy for treating clinically isolated syndrome without MRI-positive lesions that meet the dissemination in time according to the McDonald criteria.<xref ref-type="bibr" rid="article-159964.r26">[26]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Fingolimod therapy has also proven effective as a first-line treatment for patients with multiple sclerosis who have a high lesion burden, multiple active lesions on gadolinium-enhancing T1 MRI sequences, multiple relapses in a year, marked progression of deficits, or incomplete recovery from relapses.<xref ref-type="bibr" rid="article-159964.r2">[2]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Fingolimod therapy can be initiated in patients with mild disease progression refractory to other medications, provided they understand the adverse effects of the medication and monitoring requirements.<xref ref-type="bibr" rid="article-159964.r2">[2]</xref></p>
          </list-item>
        </list>
        <p><bold>Fingolimod as escalation therapy for RRMS: </bold>Fingolimod is considered an escalation therapy for the patient profiles mentioned below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Patients who are asymptomatic but have MRI demonstrating gadolinium-enhancing lesions, indicating clinically silent multiple sclerosis, are evaluated for alternative treatment.<xref ref-type="bibr" rid="article-159964.r2">[2]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients who experience more than one relapse per year.<xref ref-type="bibr" rid="article-159964.r2">[2]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients with more than&#x000a0;9 T2 lesions on MRI at any given time.<xref ref-type="bibr" rid="article-159964.r2">[2]</xref></p>
          </list-item>
        </list>
        <p><bold>Fingolimod as de-escalation therapy for RRMS: </bold>Fingolimod offers viable options under specific conditions when considering de-escalation strategies for RRMS<bold>.</bold></p>
        <list list-type="bullet">
          <list-item>
            <p>Fingolimod therapy may be initiated&#x000a0;after discontinuing disease-modifying therapy. Patients should be closely monitored for overlapping immunosuppressant effects.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Initiating fingolimod 8 to 12 weeks after natalizumab therapy has been shown to reduce relapse rates compared to glatiramer acetate or no treatment.<xref ref-type="bibr" rid="article-159964.r2">[2]</xref><xref ref-type="bibr" rid="article-159964.r27">[27]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Before initiating fingolimod therapy, physicians should&#x000a0;rule out disease-modifying therapy&#x02013;related diseases, such as progressive multifocal leukoencephalopathy (PML), infections, tumors, and cardiac pathology.<xref ref-type="bibr" rid="article-159964.r28">[28]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Discontinuation of Fingolimod</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Discontinuing fingolimod may cause relapse in up to 30% of patients within the first 6 months after discontinuing the therapy. Outcomes are better in patients who initiate a second medication within 2 months of fingolimod therapy.<xref ref-type="bibr" rid="article-159964.r29">[29]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Predictors of disease relapse include a higher relapse rate in the year before discontinuing, female sex, younger age, and a higher Expanded Disability Status scale score.<xref ref-type="bibr" rid="article-159964.r30">[30]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold>&#x000a0;Although dosage adjustment is not recommended, monitoring of liver function is advised in patients with mild-to-moderate hepatic dysfunction. Fingolimod is contraindicated in patients with severe hepatic dysfunction (Child-Pugh class C).<xref ref-type="bibr" rid="article-159964.r31">[31]</xref>&#x000a0;</p>
        <p><bold>Renal impairment: </bold>Protein binding and half-life of fingolimod in patients with renal impairment are similar to those in healthy subjects. Standard dosing is generally considered safe for patients with mild, moderate, or severe renal impairment, although further studies would be beneficial.<xref ref-type="bibr" rid="article-159964.r32">[32]</xref></p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>Fingolimod has a low molecular weight, allowing it to cross the placental membrane easily.<xref ref-type="bibr" rid="article-159964.r33">[33]</xref>&#x000a0;Preclinical data&#x000a0;suggest that sphingosine receptors might help regulate placenta and embryonic angiogenesis.<xref ref-type="bibr" rid="article-159964.r33">[33]</xref><xref ref-type="bibr" rid="article-159964.r34">[34]</xref>&#x000a0;Therefore, the FDA recommends that all women of childbearing age use at least two different forms of contraception while taking fingolimod and for 2 months after discontinuing the medication.<xref ref-type="bibr" rid="article-159964.r34">[34]</xref>&#x000a0;</p>
        <p>Abrupt discontinuation of fingolimod before and during pregnancy&#x000a0;may increase the risk of disease relapse.<xref ref-type="bibr" rid="article-159964.r35">[35]</xref>&#x000a0;Fingolimod does not appear to interact with or affect the pharmacodynamic properties of contraceptive medications; therefore, oral contraceptives are considered effective birth control in this patient population.<xref ref-type="bibr" rid="article-159964.r36">[36]</xref>&#x000a0;The fingolimod pregnancy registry is available to monitor potential fetal or maternal complications further.</p>
        <p><bold>Breastfeeding considerations:</bold>&#x000a0;Patients should be&#x000a0;informed that&#x000a0;fingolimod can be present in breast milk, and therefore, breastfeeding is not recommended while taking this medication.</p>
      </sec>
      <sec id="article-159964.s4" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most commonly reported adverse effects while taking fingolimod include headache, cough, nasopharyngitis, viral upper respiratory infections, elevated liver enzymes, back pain, nausea, diarrhea, and abdominal pain. Other potential adverse effects&#x000a0;include bradycardia, hypotension, and heart blocks. Additionally, fingolimod&#x000a0;administration increases the risk&#x000a0;of high-mortality infections such as PML, human papillomavirus (HPV), meningitis, and encephalitis. However, skin carcinoma, melanoma, and lymphoma have also been documented in patients undergoing treatment with fingolimod.<xref ref-type="bibr" rid="article-159964.r2">[2]</xref></p>
        <p>
<bold>Warnings and Precautions&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Fingolimod phosphates bind to sphingosine receptors located on the sinoatrial and atrioventricular (AV) nodes, as well as in atrial myocytes. This binding induces inward potassium flow, resulting in a negative chronotropic effect on the heart.<xref ref-type="bibr" rid="article-159964.r37">[37]</xref><xref ref-type="bibr" rid="article-159964.r38">[38]</xref>&#x000a0;Fingolimod is commonly associated with transient and asymptomatic bradycardia occurring 4 to 6 hours following the first dose administration. However, after 1 month of daily fingolimod administration, the heart rate typically normalizes to the pre-dose range.<xref ref-type="bibr" rid="article-159964.r39">[39]</xref>&#x000a0;Ventricular arrhythmia has not been reported in trials, likely due to the absence of inward rectifying potassium channels within the ventricle.<xref ref-type="bibr" rid="article-159964.r40">[40]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Dose-dependent administration of fingolimod is linked to the AV node conduction block, with the first-degree block being the most frequently observed pattern in an electrocardiogram (ECG). Conduction abnormalities may manifest within 6 hours of treatment initiation; however, these typically do not include Mobitz type II or third-degree AV block.<xref ref-type="bibr" rid="article-159964.r39">[39]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients treated with fingolimod commonly experience reversible lymphopenia, which heightens the risk of developing opportunistic infections such as cryptococcal, herpes simplex virus, and nasopharyngitis.<xref ref-type="bibr" rid="article-159964.r27">[27]</xref><xref ref-type="bibr" rid="article-159964.r41">[41]</xref><xref ref-type="bibr" rid="article-159964.r42">[42]</xref>&#x000a0;Coadministration of valacyclovir has proven beneficial and well-tolerated by patients, with resolution of herpetic diseases typically occurring within a few weeks.<xref ref-type="bibr" rid="article-159964.r6">[6]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>PML is not commonly associated with fingolimod therapy. However, in known cases of fingolimod-associated PML, the clinical presentation is nonspecific, which may delay or underestimate the diagnosis of the conditions.<xref ref-type="bibr" rid="article-159964.r43">[43]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Fingolimod-associated cystic macular edema has been reported to be dose-dependent. While ophthalmological complications are rare at approved doses, patients with uveitis or diabetes may be at increased risk.<xref ref-type="bibr" rid="article-159964.r44">[44]</xref><xref ref-type="bibr" rid="article-159964.r45">[45]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Transaminitis requiring persistent monitoring has been documented with fingolimod therapy. In cases where acute liver dysfunction develops, and other alternative etiologies have been ruled out, physicians should consider discontinuing fingolimod therapy. For viral hepatitis, discontinuation is recommended until the active phase of viremia resolves. Instances of fulminant hepatic failure requiring transplantation have been documented.<xref ref-type="bibr" rid="article-159964.r31">[31]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>A mild increase in blood pressure has been reported with fingolimod therapy. However, this increase has been effectively controlled with antiarrhythmics and typically does not necessitate discontinuation of fingolimod.<xref ref-type="bibr" rid="article-159964.r6">[6]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In rare instances, the initiation or abrupt termination of fingolimod can precipitate tumefactive multiple sclerosis (TMS). Therefore, TMS should be suspected if a patient presents with a severe or atypical multiple sclerosis flare.<xref ref-type="bibr" rid="article-159964.r46">[46]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>HPV vaccines are recommended for patients initiating fingolimod treatment due to the marked immunosuppression associated with fingolimod therapy, which may increase the risk of infection or reactivation of HPV-related diseases.<xref ref-type="bibr" rid="article-159964.r47">[47]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Multiple cases of basal cell carcinoma have been documented in patients receiving fingolimod treatment.<xref ref-type="bibr" rid="article-159964.r27">[27]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-159964.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Fingolimod is contraindicated in patients who have experienced cardiovascular events within the last 6 months, including myocardial infarction, unstable angina, stroke, transient ischemic attack, class III/IV heart failure, or decompensated heart failure requiring hospitalization. Additionally, patients with a history of Mobitz type II heart block, third-degree AV block, or sick sinus syndrome should avoid fingolimod unless they have a working pacemaker. Fingolimod can potentially prolong the QTc interval; therefore, physicians should refrain from initiating fingolimod treatment in patients with a baseline QTc of 500 ms or longer.<xref ref-type="bibr" rid="article-159964.r2">[2]</xref></p>
        <p>Moreover, it is crucial for the medical team to thoroughly assess patients with a history of cardiac arrhythmias, as fingolimod is contraindicated in patients taking certain antiarrhythmic medications. If a patient is on antiarrhythmic medications that block fast sodium channels (class Ia) or potassium channels (class III), alternative treatments to fingolimod must be considered. Finally, if patients develop a hypersensitivity reaction to fingolimod, the medical team should immediately discontinue the treatment and take adequate actions to guarantee the patient's safety.<xref ref-type="bibr" rid="article-159964.r2">[2]</xref></p>
      </sec>
      <sec id="article-159964.s6" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Before starting&#x000a0;fingolimod therapy, medical providers should complete the following measures:</p>
        <list list-type="bullet">
          <list-item>
            <p>Perform baseline vital signs assessments.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Conduct a complete blood count, hepatic function test, and pregnancy test.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Screen for severe liver failure, chronic hepatitis, and HIV infection.<xref ref-type="bibr" rid="article-159964.r2">[2]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Obtain varicella-zoster virus (VZV) antibody titers to assess immunity status.<xref ref-type="bibr" rid="article-159964.r2">[2]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Conduct an ophthalmological evaluation to rule out macular edema.<xref ref-type="bibr" rid="article-159964.r45">[45]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Obtain an ECG to establish baseline QTc interval and evaluate for preexisting heart blocks.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Review the patient's medication list to identify any drugs that may cause bradycardia, such as &#x003b2;-blockers or antiarrhythmics, and consider alternative therapy if necessary.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Assess the patient's history for malignancy and consider dermatological evaluation to rule out skin malignancies.<xref ref-type="bibr" rid="article-159964.r2">[2]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Evaluate for the presence of neuromyelitis optica by obtaining aquaporin-4 antibodies, especially in patients presenting with ocular symptoms suggestive of this condition.<xref ref-type="bibr" rid="article-159964.r48">[48]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Advise patients to utilize at least 2 effective contraceptive methods during the course of fingolimod therapy and for 2 months following discontinuation of therapy.<xref ref-type="bibr" rid="article-159964.r2">[2]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Educate patients about the risk of developing tumefactive lesions within 6 months of starting fingolimod therapy.<xref ref-type="bibr" rid="article-159964.r46">[46]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Perform a brain MRI scan with and without contrast.<xref ref-type="bibr" rid="article-159964.r2">[2]</xref></p>
          </list-item>
        </list>
        <p>After the first dose of fingolimod therapy is administered, various parameters, including vital signs, ECG, and baseline electrolytes, must be monitored. Hourly evaluation of vital signs, especially the patient's heart rate, is essential for up to 6 hours post-initiation due to fingolimod's potential to induce bradycardia.&#x000a0;If the patient's heart rate falls below 40 bpm or 30% of the baseline value, or if symptomatic bradycardia develops, therapy should be immediately discontinued by the medical providers. Patients must then undergo prolonged cardiac monitoring for their safety.</p>
        <p>An ECG should be repeated 6 hours after administration to monitor for QTc prolongation, new-onset cardiac block, or arrhythmias. Patients should be promptly transferred to the nearest cardiac center for further evaluation if abnormalities are detected on the ECG. Patients at risk for developing torsades de pointes should be monitored at the discretion of the medical team for an extended interval; however, it is advisable to correct electrolyte imbalances and keep a cardiologist informed to ensure a safe environment for the patient. Patients at risk for torsades de pointes include those with preexisting hypokalemia, hypomagnesemia, and congenital long QT syndrome.<xref ref-type="bibr" rid="article-159964.r37">[37]</xref><xref ref-type="bibr" rid="article-159964.r38">[38]</xref><xref ref-type="bibr" rid="article-159964.r39">[39]</xref></p>
        <p>Parameters that should be regularly monitored during fingolimod treatment aim to prevent severe lymphopenia and macular edema. These include white blood cell count, inflammatory markers, complete metabolic panel, and pregnancy status, which should be assessed after 2 and 4 weeks of initiating fingolimod therapy. Subsequently, physicians should conduct laboratory monitoring every 3 months until the treatment is discontinued.<xref ref-type="bibr" rid="article-159964.r2">[2]</xref>&#x000a0;If&#x000a0;the lymphocyte count drops below 200 cells/mL, physicians should halt fingolimod therapy until the count improves to 600 cells/mL.<xref ref-type="bibr" rid="article-159964.r2">[2]</xref>&#x000a0;Patients with a low baseline lymphocyte count or a baseline metabolic index&#x000a0;below&#x000a0;18.5 kg/m<sup>2</sup> are at higher risk of developing lymphopenia.<xref ref-type="bibr" rid="article-159964.r49">[49]</xref>&#x000a0;</p>
        <p>Fingolimod therapy should be discontinued if liver enzymes remain elevated to 5 times the upper limit on&#x000a0;2 consecutive labs&#x000a0;3 months apart.<xref ref-type="bibr" rid="article-159964.r2">[2]</xref><xref ref-type="bibr" rid="article-159964.r31">[31]</xref>&#x000a0;For women of childbearing age, contraceptive treatment is imperative while on therapy; if pregnancy is desired, fingolimod treatment must be halted at least 2 months before conception.<xref ref-type="bibr" rid="article-159964.r34">[34]</xref>&#x000a0;Ophthalmological evaluation should be&#x000a0;performed by an ophthalmologist&#x000a0;3 to&#x000a0;4 months after starting fingolimod therapy to rule out the development of macular edema. If macular edema is detected, physicians should promptly discontinue fingolimod treatment. Patients with diabetes or a history of uveitis should undergo annual ophthalmological evaluations due to their heightened risk for ophthalmological complications.<xref ref-type="bibr" rid="article-159964.r2">[2]</xref></p>
      </sec>
      <sec id="article-159964.s7" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>The toxic effects associated with fingolimod primarily involve potential systemic complications. Cardiac toxicities such as asystole and sudden cardiac death can occur due to the development of heart blocks.<xref ref-type="bibr" rid="article-159964.r50">[50]</xref>&#x000a0;Severe&#x000a0;immunosuppression, particularly notable in patients who have undergone postrenal transplant, may develop, significantly elevating the risk for potentially fatal opportunistic infections.<xref ref-type="bibr" rid="article-159964.r51">[51]</xref>&#x000a0;Myelosuppression is not an adverse effect of fingolimod therapy.<xref ref-type="bibr" rid="article-159964.r52">[52]</xref>&#x000a0;However, dose-dependent development of macular edema has been documented, affecting the patient's vision, with higher occurrence rates noted in those taking the 5 mg dose.<xref ref-type="bibr" rid="article-159964.r53">[53]</xref>&#x000a0;Efforts to mitigate toxicity are ongoing, with the development of multiple S1PR-specific antagonists aimed at reducing adverse effects.&#x000a0;</p>
      </sec>
      <sec id="article-159964.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Patients with RRMS face significant challenges due to deteriorating motor and cognitive function, particularly when the disease manifests in young adulthood. Early diagnosis and effective management strategies are crucial for preserving function over time and alleviating the burden of the disease. Ensuring treatment efficacy, reducing disability, and enhancing patient outcomes in RRMS care require a collaborative, multidisciplinary approach among healthcare professionals. Neurologists, primary care physicians, nurses, physical and occupational therapists, pharmacists, and other specialists involved in treating patients with&#x000a0;RRMS should possess a comprehensive understanding of the clinical diagnosis, disease progression, and available therapies, including potential complications.</p>
        <p>The emergence of fingolimod as a novel disease-modifying therapy for RRMS expands the scope of patient care to encompass a collaborative approach. Patients receiving fingolimod treatment benefit from multidisciplinary care involving specialists such as cardiologists, infectious disease experts, immunologists, ophthalmologists, oncologists, and hematologists. This collaborative effort aims to implement preventive measures, conduct screenings, and promptly address any therapy-related complications to optimize patient outcomes.</p>
        <p>Adopting a strategic approach is paramount to mitigate treatment-related adverse effects and ensure diligent monitoring during therapy initiation and maintenance. Effective communication between healthcare providers and patients is essential to uphold patient autonomy, compliance, safety, and treatment effectiveness. With a comprehensive understanding of fingolimod's mechanism of action, clinical indications, potential adverse effects, monitoring parameters, and contraindications, healthcare professionals can empower individuals with multiple sclerosis to achieve a more normal&#x000a0;life.</p>
      </sec>
      <sec id="article-159964.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=159964&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=159964">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/159964/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=159964">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-159964.s10">
        <title>References</title>
        <ref id="article-159964.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pournajaf</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dargahi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Javan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pourgholami</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Molecular Pharmacology and Novel Potential Therapeutic Applications of Fingolimod.</article-title>
            <source>Front Pharmacol</source>
            <year>2022</year>
            <volume>13</volume>
            <fpage>807639</fpage>
            <pub-id pub-id-type="pmid">35250559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ayzenberg</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hoepner</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kleiter</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations.</article-title>
            <source>Ther Clin Risk Manag</source>
            <year>2016</year>
            <volume>12</volume>
            <fpage>261</fpage>
            <page-range>261-72</page-range>
            <pub-id pub-id-type="pmid">26929636</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roy</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Alotaibi</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Freedman</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis.</article-title>
            <source>CNS Drugs</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>35</volume>
            <issue>4</issue>
            <fpage>385</fpage>
            <page-range>385-402</page-range>
            <pub-id pub-id-type="pmid">33797705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>David</surname>
                <given-names>OJ</given-names>
              </name>
              <name>
                <surname>Kovarik</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Schmouder</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacokinetics of fingolimod.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2012</year>
            <month>Jan</month>
            <day>01</day>
            <volume>51</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-28</page-range>
            <pub-id pub-id-type="pmid">22149256</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McGinley</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.</article-title>
            <source>Lancet</source>
            <year>2021</year>
            <month>Sep</month>
            <day>25</day>
            <volume>398</volume>
            <issue>10306</issue>
            <fpage>1184</fpage>
            <page-range>1184-1194</page-range>
            <pub-id pub-id-type="pmid">34175020</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ordo&#x000f1;ez-Boschetti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rey</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cruz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sinha</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Frider</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Alvarenga</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study.</article-title>
            <source>Adv Ther</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>32</volume>
            <issue>7</issue>
            <fpage>626</fpage>
            <page-range>626-35</page-range>
            <pub-id pub-id-type="pmid">26170105</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ji</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Sphingosine 1-phosphate receptor, a new therapeutic direction in different diseases.</article-title>
            <source>Biomed Pharmacother</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>153</volume>
            <fpage>113341</fpage>
            <pub-id pub-id-type="pmid">35785704</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anwar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Post-translational modifications of S1PR1 and endothelial barrier regulation.</article-title>
            <source>Biochim Biophys Acta Mol Cell Biol Lipids</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>1865</volume>
            <issue>9</issue>
            <fpage>158760</fpage>
            <pub-id pub-id-type="pmid">32585303</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yamashita</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Suda</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>A Novel Function of Sphingolipid Signaling via S1PR3 in Hematopoietic and Leukemic Stem Cells.</article-title>
            <source>Blood Cancer Discov</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-5</page-range>
            <pub-id pub-id-type="pmid">34661148</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saba</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Hla</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Point-counterpoint of sphingosine 1-phosphate metabolism.</article-title>
            <source>Circ Res</source>
            <year>2004</year>
            <month>Apr</month>
            <day>02</day>
            <volume>94</volume>
            <issue>6</issue>
            <fpage>724</fpage>
            <page-range>724-34</page-range>
            <pub-id pub-id-type="pmid">15059942</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwab</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Cyster</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Finding a way out: lymphocyte egress from lymphoid organs.</article-title>
            <source>Nat Immunol</source>
            <year>2007</year>
            <month>Dec</month>
            <volume>8</volume>
            <issue>12</issue>
            <fpage>1295</fpage>
            <page-range>1295-301</page-range>
            <pub-id pub-id-type="pmid">18026082</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shea</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Opal</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>The Role of S1PR3 in Protection from Bacterial Sepsis.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2017</year>
            <month>Dec</month>
            <day>15</day>
            <volume>196</volume>
            <issue>12</issue>
            <fpage>1500</fpage>
            <page-range>1500-1502</page-range>
            <pub-id pub-id-type="pmid">28910137</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olesch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sirait-Fischer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Berkefeld</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fink</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Susen</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Ritter</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Michels</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Steinhilber</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Greten</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Savai</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Takeda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Br&#x000fc;ne</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Weigert</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>S1PR4 ablation reduces tumor growth and improves chemotherapy via CD8+ T cell expansion.</article-title>
            <source>J Clin Invest</source>
            <year>2020</year>
            <month>Oct</month>
            <day>01</day>
            <volume>130</volume>
            <issue>10</issue>
            <fpage>5461</fpage>
            <page-range>5461-5476</page-range>
            <pub-id pub-id-type="pmid">32663191</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chun</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Giovannoni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hunter</surname>
                <given-names>SF</given-names>
              </name>
            </person-group>
            <article-title>Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects.</article-title>
            <source>Drugs</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>81</volume>
            <issue>2</issue>
            <fpage>207</fpage>
            <page-range>207-231</page-range>
            <pub-id pub-id-type="pmid">33289881</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paugh</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Payne</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Barbour</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Milstien</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Spiegel</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2.</article-title>
            <source>FEBS Lett</source>
            <year>2003</year>
            <month>Nov</month>
            <day>06</day>
            <volume>554</volume>
            <issue>1-2</issue>
            <fpage>189</fpage>
            <page-range>189-93</page-range>
            <pub-id pub-id-type="pmid">14596938</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsai</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway: Therapeutic Targets in Autoimmunity and Inflammation.</article-title>
            <source>Drugs</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>76</volume>
            <issue>11</issue>
            <fpage>1067</fpage>
            <page-range>1067-79</page-range>
            <pub-id pub-id-type="pmid">27318702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brinkmann</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Heise</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Albert</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cottens</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hof</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bruns</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Prieschl</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Baumruker</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hiestand</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Zollinger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>KR</given-names>
              </name>
            </person-group>
            <article-title>The immune modulator FTY720 targets sphingosine 1-phosphate receptors.</article-title>
            <source>J Biol Chem</source>
            <year>2002</year>
            <month>Jun</month>
            <day>14</day>
            <volume>277</volume>
            <issue>24</issue>
            <fpage>21453</fpage>
            <page-range>21453-7</page-range>
            <pub-id pub-id-type="pmid">11967257</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Qian</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>An</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Fingolimod Attenuates Lung Injury and Cardiac Dysfunction after Traumatic Brain Injury.</article-title>
            <source>J Neurotrauma</source>
            <year>2020</year>
            <month>Oct</month>
            <day>01</day>
            <volume>37</volume>
            <issue>19</issue>
            <fpage>2131</fpage>
            <page-range>2131-2140</page-range>
            <pub-id pub-id-type="pmid">32434456</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Foster</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Mechtcheriakova</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Storch</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Balatoni</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Howard</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Bornancin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wlachos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sobanov</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kinnunen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baumruker</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage.</article-title>
            <source>Brain Pathol</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>254</fpage>
            <page-range>254-66</page-range>
            <pub-id pub-id-type="pmid">18540945</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anastasiadou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kn&#x000f6;ll</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>The multiple sclerosis drug fingolimod (FTY720) stimulates neuronal gene expression, axonal growth and regeneration.</article-title>
            <source>Exp Neurol</source>
            <year>2016</year>
            <month>May</month>
            <volume>279</volume>
            <fpage>243</fpage>
            <page-range>243-260</page-range>
            <pub-id pub-id-type="pmid">26980486</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Forrest</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Hajdu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bergstrom</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Card</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Doherty</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hale</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Keohane</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Meyers</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Milligan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mills</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nomura</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rosen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rosenbach</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shei</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>II</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>West</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Proia</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Mandala</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes.</article-title>
            <source>J Pharmacol Exp Ther</source>
            <year>2004</year>
            <month>May</month>
            <volume>309</volume>
            <issue>2</issue>
            <fpage>758</fpage>
            <page-range>758-68</page-range>
            <pub-id pub-id-type="pmid">14747617</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>T&#x000f6;lle</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Levkau</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Keul</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Brinkmann</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Giebing</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sch&#x000f6;nfelder</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sch&#x000e4;fers</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>von Wnuck Lipinski</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jankowski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jankowski</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Chun</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zidek</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Van der Giet</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Immunomodulator FTY720 Induces eNOS-dependent arterial vasodilatation via the lysophospholipid receptor S1P3.</article-title>
            <source>Circ Res</source>
            <year>2005</year>
            <month>Apr</month>
            <day>29</day>
            <volume>96</volume>
            <issue>8</issue>
            <fpage>913</fpage>
            <page-range>913-20</page-range>
            <pub-id pub-id-type="pmid">15802614</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bryan</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>You</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>McQuiston</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lazzarini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Qiu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Sheridan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nuesslein-Hildesheim</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Del Poeta</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>FTY720 reactivates cryptococcal granulomas in mice through S1P receptor 3 on macrophages.</article-title>
            <source>J Clin Invest</source>
            <year>2020</year>
            <month>Sep</month>
            <day>01</day>
            <volume>130</volume>
            <issue>9</issue>
            <fpage>4546</fpage>
            <page-range>4546-4560</page-range>
            <pub-id pub-id-type="pmid">32484801</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liao</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Goetzl</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Cutting edge: Alternative signaling of Th17 cell development by sphingosine 1-phosphate.</article-title>
            <source>J Immunol</source>
            <year>2007</year>
            <month>May</month>
            <day>01</day>
            <volume>178</volume>
            <issue>9</issue>
            <fpage>5425</fpage>
            <page-range>5425-8</page-range>
            <pub-id pub-id-type="pmid">17442922</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mehling</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lindberg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Raulf</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kuhle</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hess</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kappos</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Brinkmann</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.</article-title>
            <source>Neurology</source>
            <year>2010</year>
            <month>Aug</month>
            <day>03</day>
            <volume>75</volume>
            <issue>5</issue>
            <fpage>403</fpage>
            <page-range>403-10</page-range>
            <pub-id pub-id-type="pmid">20592255</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Polman</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Reingold</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Banwell</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Clanet</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Filippi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fujihara</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Havrdova</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hutchinson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kappos</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lublin</surname>
                <given-names>FD</given-names>
              </name>
              <name>
                <surname>Montalban</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>O'Connor</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sandberg-Wollheim</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Waubant</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Weinshenker</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wolinsky</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.</article-title>
            <source>Ann Neurol</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>69</volume>
            <issue>2</issue>
            <fpage>292</fpage>
            <page-range>292-302</page-range>
            <pub-id pub-id-type="pmid">21387374</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rae-Grant</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Marrie</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Rabinstein</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cree</surname>
                <given-names>BAC</given-names>
              </name>
              <name>
                <surname>Gronseth</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Haboubi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Halper</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hosey</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Lisak</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pelletier</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Potrebic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sitcov</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sommers</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Stachowiak</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Getchius</surname>
                <given-names>TSD</given-names>
              </name>
              <name>
                <surname>Merillat</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Pringsheim</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.</article-title>
            <source>Neurology</source>
            <year>2018</year>
            <month>Apr</month>
            <day>24</day>
            <volume>90</volume>
            <issue>17</issue>
            <fpage>777</fpage>
            <page-range>777-788</page-range>
            <pub-id pub-id-type="pmid">29686116</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lyons</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>McCarthy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Everage</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kapadia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Singhal</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Smirnakis</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Progressive multifocal leukoencephalopathy outcomes in patients with multiple sclerosis treated with dimethyl fumarate.</article-title>
            <source>Mult Scler J Exp Transl Clin</source>
            <year>2022</year>
            <season>Oct-Dec</season>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>20552173221132469</fpage>
            <pub-id pub-id-type="pmid">36387034</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rinaldi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Seppi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Calabrese</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Perini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gallo</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings.</article-title>
            <source>Mult Scler</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>18</volume>
            <issue>11</issue>
            <fpage>1640</fpage>
            <page-range>1640-3</page-range>
            <pub-id pub-id-type="pmid">23100526</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roos</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Malpas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Leray</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Horakova</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Havrdova</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Debouverie</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Patti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>De Seze</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Izquierdo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Eichau</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Edan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Prat</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Girard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ozakbas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Grammond</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zephir</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ciron</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Maillart</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Moreau</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Amato</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Labauge</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Alroughani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Buzzard</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Skibina</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Terzi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Laplaud</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Grand'Maison</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lebrun-Frenay</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cartechini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Boz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lechner-Scott</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Clavelou</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Stankoff</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Prevost</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kappos</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pelletier</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shaygannejad</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Yamout</surname>
                <given-names>BI</given-names>
              </name>
              <name>
                <surname>Khoury</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Gerlach</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Spitaleri</surname>
                <given-names>DLA</given-names>
              </name>
              <name>
                <surname>Van Pesch</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gout</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Turkoglu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Heinzlef</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Thouvenot</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>McCombe</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Soysal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bourre</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Slee</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Castillo-Trivino</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bakchine</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ampapa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Wahab</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Macdonell</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Aguera-Morales</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cabre</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ben</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Van der Walt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Laureys</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Van Hijfte</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ramo-Tello</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Maubeuge</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hodgkinson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez-Menoyo</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Barnett</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Labeyrie</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vucic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sidhom</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Gouider</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Csepany</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sotoca</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>de Gans</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Al-Asmi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fragoso</surname>
                <given-names>YD</given-names>
              </name>
              <name>
                <surname>Vukusic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Butzkueven</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kalincik</surname>
                <given-names>T</given-names>
              </name>
              <collab>MSBase and OFSEP</collab>
            </person-group>
            <article-title>Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.</article-title>
            <source>Neurology</source>
            <year>2022</year>
            <month>Oct</month>
            <day>25</day>
            <volume>99</volume>
            <issue>17</issue>
            <fpage>e1926</fpage>
            <page-range>e1926-e1944</page-range>
            <pub-id pub-id-type="pmid">35977837</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Biolato</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bianco</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lucchini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gasbarrini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mirabella</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grieco</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review.</article-title>
            <source>CNS Drugs</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>35</volume>
            <issue>8</issue>
            <fpage>861</fpage>
            <page-range>861-880</page-range>
            <pub-id pub-id-type="pmid">34319570</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>David</surname>
                <given-names>OJ</given-names>
              </name>
              <name>
                <surname>Pryce</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Meiser</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Picard</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Emotte</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kobalava</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Moiseev</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Schmouder</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of fingolimod and metabolites in subjects with severe renal impairment: An open-label, single-dose, parallel-group study.</article-title>
            <source>Int J Clin Pharmacol Ther</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>53</volume>
            <issue>10</issue>
            <fpage>847</fpage>
            <page-range>847-54</page-range>
            <pub-id pub-id-type="pmid">26308173</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Varyt&#x00117;</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Arlauskien&#x00117;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rama&#x00161;auskait&#x00117;</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Pregnancy and multiple sclerosis: an update.</article-title>
            <source>Curr Opin Obstet Gynecol</source>
            <year>2021</year>
            <month>Oct</month>
            <day>01</day>
            <volume>33</volume>
            <issue>5</issue>
            <fpage>378</fpage>
            <page-range>378-383</page-range>
            <pub-id pub-id-type="pmid">34310364</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karlsson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Francis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Koren</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Heining</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kappos</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis.</article-title>
            <source>Neurology</source>
            <year>2014</year>
            <month>Feb</month>
            <day>25</day>
            <volume>82</volume>
            <issue>8</issue>
            <fpage>674</fpage>
            <page-range>674-80</page-range>
            <pub-id pub-id-type="pmid">24463630</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yeh</surname>
                <given-names>WZ</given-names>
              </name>
              <name>
                <surname>Widyastuti</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Van der Walt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stankovich</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Havrdova</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Horakova</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vodehnalova</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ozakbas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Eichau</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Duquette</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kalincik</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Patti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Boz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Terzi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yamout</surname>
                <given-names>BI</given-names>
              </name>
              <name>
                <surname>Lechner-Scott</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sola</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Skibina</surname>
                <given-names>OG</given-names>
              </name>
              <name>
                <surname>Barnett</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Onofrj</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>S&#x000e1;</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>McCombe</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Grammond</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ampapa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Grand'Maison</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bergamaschi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Spitaleri</surname>
                <given-names>DLA</given-names>
              </name>
              <name>
                <surname>Van Pesch</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Cartechini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hodgkinson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Soysal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Saiz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gresle</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Uher</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Maimone</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Turkoglu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hupperts</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Amato</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Granella</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Oreja-Guevara</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Altintas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Macdonell</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Castillo-Trivino</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Butzkueven</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Alroughani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jokubaitis</surname>
                <given-names>VG</given-names>
              </name>
              <collab>MSBase Study Group</collab>
            </person-group>
            <article-title>Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis.</article-title>
            <source>Neurology</source>
            <year>2021</year>
            <month>Jun</month>
            <day>15</day>
            <volume>96</volume>
            <issue>24</issue>
            <fpage>e2989</fpage>
            <page-range>e2989-e3002</page-range>
            <pub-id pub-id-type="pmid">33879599</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>David</surname>
                <given-names>OJ</given-names>
              </name>
              <name>
                <surname>Ocwieja</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Meiser</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Emotte</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jakab</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wemer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>den Daas</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Schmouder</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study results.</article-title>
            <source>Int J Clin Pharmacol Ther</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>50</volume>
            <issue>8</issue>
            <fpage>540</fpage>
            <page-range>540-4</page-range>
            <pub-id pub-id-type="pmid">22735460</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brinkmann</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Billich</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baumruker</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Heining</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schmouder</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Francis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Aradhye</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Burtin</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.</article-title>
            <source>Nat Rev Drug Discov</source>
            <year>2010</year>
            <month>Nov</month>
            <volume>9</volume>
            <issue>11</issue>
            <fpage>883</fpage>
            <page-range>883-97</page-range>
            <pub-id pub-id-type="pmid">21031003</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brinkmann</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology.</article-title>
            <source>Pharmacol Ther</source>
            <year>2007</year>
            <month>Jul</month>
            <volume>115</volume>
            <issue>1</issue>
            <fpage>84</fpage>
            <page-range>84-105</page-range>
            <pub-id pub-id-type="pmid">17561264</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>DiMarco</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>O'Connor</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Reder</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Zhang-Auberson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kappos</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>First-dose effects of fingolimod: Pooled safety data from three phase 3 studies.</article-title>
            <source>Mult Scler Relat Disord</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>3</volume>
            <issue>5</issue>
            <fpage>629</fpage>
            <page-range>629-38</page-range>
            <pub-id pub-id-type="pmid">26265275</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gaborit</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Le Bouter</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Szuts</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Varro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Escande</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nattel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Demolombe</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Regional and tissue specific transcript signatures of ion channel genes in the non-diseased human heart.</article-title>
            <source>J Physiol</source>
            <year>2007</year>
            <month>Jul</month>
            <day>15</day>
            <volume>582</volume>
            <issue>Pt 2</issue>
            <fpage>675</fpage>
            <page-range>675-93</page-range>
            <pub-id pub-id-type="pmid">17478540</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cervera</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>[Infections and fingolimod].</article-title>
            <source>Rev Neurol</source>
            <year>2012</year>
            <month>Aug</month>
            <day>16</day>
            <volume>55</volume>
            <issue>4</issue>
            <fpage>227</fpage>
            <page-range>227-37</page-range>
            <pub-id pub-id-type="pmid">22829086</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ziemssen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Albrecht</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Klotz</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Haas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lassek</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Winkelmann</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Ettle</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schulze-Topphoff</surname>
                <given-names>U</given-names>
              </name>
              <collab>PANGAEA study group</collab>
            </person-group>
            <article-title>Long-term real-world effectiveness and safety of fingolimod over 5&#x000a0;years in Germany.</article-title>
            <source>J Neurol</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>269</volume>
            <issue>6</issue>
            <fpage>3276</fpage>
            <page-range>3276-3285</page-range>
            <pub-id pub-id-type="pmid">34982201</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nishiyama</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Misu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shishido-Hara</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nakamichi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Saijo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Takai</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Takei</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kuroda</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Saito</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tominaga</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nakashima</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Fujihara</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Aoki</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Fingolimod-associated PML with mild IRIS in MS: A clinicopathologic study.</article-title>
            <source>Neurol Neuroimmunol Neuroinflamm</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>e415</fpage>
            <pub-id pub-id-type="pmid">29725611</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pul</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Osmanovic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schmalstieg</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pielen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pars</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Schwenkenbecher</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>S&#x000fc;hs</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Yildiz</surname>
                <given-names>&#x000d6;</given-names>
              </name>
              <name>
                <surname>Frank</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Stangel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Skripuletz</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Fingolimod Associated Bilateral Cystoid Macular Edema-Wait and See?</article-title>
            <source>Int J Mol Sci</source>
            <year>2016</year>
            <month>Dec</month>
            <day>14</day>
            <volume>17</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">27983657</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zarbin</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Jampol</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Jager</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Reder</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Francis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis.</article-title>
            <source>Ophthalmology</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>120</volume>
            <issue>7</issue>
            <fpage>1432</fpage>
            <page-range>1432-9</page-range>
            <pub-id pub-id-type="pmid">23531349</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Croteau</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tobenkin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brinker</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kortepeter</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Tumefactive multiple sclerosis in association with fingolimod initiation and discontinuation.</article-title>
            <source>Mult Scler</source>
            <year>2021</year>
            <month>May</month>
            <volume>27</volume>
            <issue>6</issue>
            <fpage>903</fpage>
            <page-range>903-912</page-range>
            <pub-id pub-id-type="pmid">32662718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Triplett</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kermode</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Corbett</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reddel</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <article-title>Warts and all: Fingolimod and unusual HPV-associated lesions.</article-title>
            <source>Mult Scler</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>25</volume>
            <issue>11</issue>
            <fpage>1547</fpage>
            <page-range>1547-1550</page-range>
            <pub-id pub-id-type="pmid">30427266</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kleiter</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gold</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders.</article-title>
            <source>Neurotherapeutics</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>70</fpage>
            <page-range>70-83</page-range>
            <pub-id pub-id-type="pmid">26597098</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Warnke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dehmel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ramanujam</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Holmen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nordin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wolfram</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Leussink</surname>
                <given-names>VI</given-names>
              </name>
              <name>
                <surname>Hartung</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Olsson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kieseier</surname>
                <given-names>BC</given-names>
              </name>
            </person-group>
            <article-title>Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia.</article-title>
            <source>Neurology</source>
            <year>2014</year>
            <month>Dec</month>
            <day>02</day>
            <volume>83</volume>
            <issue>23</issue>
            <fpage>2153</fpage>
            <page-range>2153-7</page-range>
            <pub-id pub-id-type="pmid">25361781</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hengstman</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Kusters</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Sudden cardiac death in multiple sclerosis caused by active demyelination of the medulla oblongata.</article-title>
            <source>Mult Scler</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>17</volume>
            <issue>9</issue>
            <fpage>1146</fpage>
            <page-range>1146-8</page-range>
            <pub-id pub-id-type="pmid">21586485</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tedesco-Silva</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Szakaly</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Shoker</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sommerer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yoshimura</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Schena</surname>
                <given-names>FP</given-names>
              </name>
              <name>
                <surname>Cremer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hmissi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>P</given-names>
              </name>
              <collab>FTY720 2218 Clinical Study Group</collab>
            </person-group>
            <article-title>FTY720 versus mycophenolate mofetil in de novo renal transplantation: six-month results of a double-blind study.</article-title>
            <source>Transplantation</source>
            <year>2007</year>
            <month>Oct</month>
            <day>15</day>
            <volume>84</volume>
            <issue>7</issue>
            <fpage>885</fpage>
            <page-range>885-92</page-range>
            <pub-id pub-id-type="pmid">17984842</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Barkhof</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Comi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hartung</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Khatri</surname>
                <given-names>BO</given-names>
              </name>
              <name>
                <surname>Montalban</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Pelletier</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Capra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gallo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Izquierdo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tiel-Wilck</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>de Vera</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stites</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aradhye</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kappos</surname>
                <given-names>L</given-names>
              </name>
              <collab>TRANSFORMS Study Group</collab>
            </person-group>
            <article-title>Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.</article-title>
            <source>N Engl J Med</source>
            <year>2010</year>
            <month>Feb</month>
            <day>04</day>
            <volume>362</volume>
            <issue>5</issue>
            <fpage>402</fpage>
            <page-range>402-15</page-range>
            <pub-id pub-id-type="pmid">20089954</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159964.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jain</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bhatti</surname>
                <given-names>MT</given-names>
              </name>
            </person-group>
            <article-title>Fingolimod-associated macular edema: incidence, detection, and management.</article-title>
            <source>Neurology</source>
            <year>2012</year>
            <month>Feb</month>
            <day>28</day>
            <volume>78</volume>
            <issue>9</issue>
            <fpage>672</fpage>
            <page-range>672-80</page-range>
            <pub-id pub-id-type="pmid">22371414</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
